Loading...
•
Jun 30, 2022
Insmed Q2 2022 Earnings Report
Insmed reported strong Q2 2022 financial results with ARIKAYCE achieving 44% year-over-year growth and all clinical programs progressing on track.
Key Takeaways
Insmed reported a strong second quarter in 2022, with ARIKAYCE revenue growing 44% year-over-year. The company's clinical programs are progressing as expected, and they are reiterating their guidance of at least 30% revenue growth in 2022 and cash runway into 2024.
ARIKAYCE revenue grew 44% year-over-year, driven by strong U.S. sales and launch activities in Japan.
Enrollment remains on track for the ARISE and ENCORE trials for ARIKAYCE and the Phase 3 ASPEN study for brensocatib.
Insmed plans to develop brensocatib in two new potential indications: chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS).
Insmed is advancing a translational medicine portfolio and anticipates filing one to two Investigational New Drug Applications per year from this portfolio.
Insmed
Insmed
Forward Guidance
Insmed expects full-year 2022 global revenues for ARIKAYCE to increase at least 30% year-over-year from 2021 and anticipates that its cash on hand will support its ongoing business into 2024.
Positive Outlook
- Commercialization and expansion of ARIKAYCE globally.
- Advancement of brensocatib, including the Phase 3 ASPEN study in patients with bronchiectasis and commercial launch readiness activities.
- Advancement of the confirmatory, frontline clinical trial program for ARIKAYCE (ARISE and ENCORE).
- Advancement of Insmed's earlier-stage pipeline, including the Phase 2 clinical development programs for TPIP.
- Advancement of Insmed's translational medicine efforts.